Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.

Blauvelt A, Muram TM, See K, Mallinckrodt CH, Crowley JJ, van de Kerkhof P.

J Dermatolog Treat. 2017 Aug 9:1-26. doi: 10.1080/09546634.2017.1365114. [Epub ahead of print]

PMID:
28792259
2.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).

Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R.

J Am Acad Dermatol. 2017 Aug;77(2):372-374. doi: 10.1016/j.jaad.2017.03.026. No abstract available.

PMID:
28711089
3.

Biosimilars for Psoriasis: Worldwide Overview of Regulatory Guidelines, Uptake and Implications for Dermatology Clinical Practice.

Cohen AD, Wu JJ, Puig L, Chimenti S, Vender R, Rajagopalan M, Romiti R, de la Cruz C, Skov L, Zachariae C, Young HS, Foley P, van der Walt JM, Naldi L, Blauvelt A.

Br J Dermatol. 2017 Jun 24. doi: 10.1111/bjd.15756. [Epub ahead of print] Review.

PMID:
28646580
4.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S.

J Eur Acad Dermatol Venereol. 2017 Jun 11. doi: 10.1111/jdv.14391. [Epub ahead of print]

PMID:
28602039
5.

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a Phase 3b, randomized, double-blinded, active-controlled, multicenter study (PSTELLAR).

Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Muñoz-Elías EJ, Callis Duffin K.

Br J Dermatol. 2017 Jun 10. doi: 10.1111/bjd.15722. [Epub ahead of print]

PMID:
28600818
6.

Infections from 7 Clinical Trials of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.

Br J Dermatol. 2017 Jun 10. doi: 10.1111/bjd.15723. [Epub ahead of print]

PMID:
28600810
7.

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.

Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6. Erratum in: Lancet. 2017 Jul 15;390(10091):230.

PMID:
28596043
8.

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.

Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB.

Br J Dermatol. 2017 May 12. doi: 10.1111/bjd.15656. [Epub ahead of print] No abstract available.

PMID:
28498514
9.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B.

Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4.

PMID:
28478972
10.

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ.

N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.

PMID:
28423301
11.

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.

Blauvelt A, Griffiths CEM, Lebwohl M, Mrowietz U, Puig L, Ball S, Zhang L, Edson-Heredia E, Warner M, Zhu B, Lin CY, Nikaï E, Dey D, Mallbris L, Reich K.

Br J Dermatol. 2017 Mar 16. doi: 10.1111/bjd.15463. [Epub ahead of print] No abstract available.

PMID:
28301048
12.

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.

Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K.

J Eur Acad Dermatol Venereol. 2017 Mar 10. doi: 10.1111/jdv.14211. [Epub ahead of print]

PMID:
28294430
13.

IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis.

Blauvelt A.

J Invest Dermatol. 2017 Mar;137(3):541-542. doi: 10.1016/j.jid.2016.11.022.

PMID:
28235443
14.

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.

Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31.

15.

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).

Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.

Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.

PMID:
28074446
16.
17.

A boxed warning for inadequate psoriasis treatment.

Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR.

Cutis. 2016 Sep;98(3):206-207. No abstract available.

PMID:
27814414
18.

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

Martin G, Strober BE, Leonardi CL, Gelfand JM, Blauvelt A, Kavanaugh A, Stein Gold L, Berman B, Rosen T, Stockfleth E.

J Clin Aesthet Dermatol. 2016 Sep;9(9 Suppl 1):S5-S29. Epub 2016 Sep 1. No abstract available.

19.

Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.

Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C.

J Drugs Dermatol. 2016 Oct 1;15(10):1226-1234.

PMID:
27741340
20.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators.

N Engl J Med. 2016 Dec 15;375(24):2335-2348. Epub 2016 Sep 30.

Supplemental Content

Loading ...
Support Center